Your Article Summary
See Latest Articles5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation
Bone Marrow Transplantation, 06/23/09
Field T et al. - The observations suggest that outcomes are similar in both groups with a trend toward decreased early relapse in patients receiving 5-azacitidine. 5-Azacitidine may be of value in stabilizing the disease, thereby allowing time for patients to reach transplant and does not appear to affect transplant outcomes.
Related Articles
Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut points to determine low, intermediate and high risk groups: The flexible HCT-CI is the best predictor of NRM and OS in a population of patients undergoing allo-RIC
Biology of Blood and Marrow Transplantation, 12/03/09
Relevance Score: 89%%
Kidney Lower Pole Pelvicaliceal Anatomy: Comparative Analysis between Intravenous Urogram and Three-Dimensional Helical Computed Tomography
Journal of Endourology, 11/30/09
Relevance Score: 88%%
Biomarkers to discern transplantation tolerance after allogeneic hematopoietic cell transplantation
Biology of Blood and Marrow Transplantation, 11/19/09
Relevance Score: 87%%
Low-dose total body irradiation and fludarabine conditioning for HLA-class I mismatched donor stem cell transplantation and immunological recovery in patients with hematological malignancies
Biology of Blood and Marrow Transplantation, 11/13/09
Relevance Score: 87%%
Outcome of 93 patients with relapse or progression following allogeneic hematopoietic cell transplantation
American Journal of Hematology, 11/10/09
Relevance Score: 87%%
Today in BMT/SCT...keeping you current
Receive free subspecialty "5-minute updates" via email
Can antigen-specific regulatory T cells protect against graft vs. host disease and spare anti-malignancy alloresponse
Haematologica, 12/18/09
Differential Destruction of Stem Cells: Implications for Targeted Cancer Stem Cell Therapy
Cancer Research, 12/18/09
Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis
Annals of Hematology, 12/18/09